Search Results

Genetown

Neuroelectrics Announces Results of Telemedicine Pilot Depression Study with Starstim tDCS Therapy

Neuroelectrics announced today study results published to the preprint server medRxiv that suggest tele-supervised at-home transcranial direct current stimulation (tDCS) using Starstim over the left dorsolateral prefrontal cortex (L-DLPFC) may improve the clinical symptoms of major depressive disorder (MDD).

March 7, 2024

·

5 min read

Genetown

Neuroelectrics Granted FDA Breakthrough Device Designation for New Therapeutic Neuromodulation Platform to Treat Refractory Focal Epilepsy

Neuroelectrics, a clinical-stage company pioneering brain stimulation therapies, has been granted FDA Breakthrough Device Designation for its Starstim® neuromodulation platform in refractory focal epilepsy.

June 30, 2021

·

2 min read

Business

Neuroelectrics Bags $17.5 Million for At-Home, Personalized Brain Stimulation Platform

Neuroelectrics, based in Barcelona, Spain with offices in Cambridge, Massachusetts, announced it had raised $17.5 million in a Series A financing round. It was led by Morningside Ventures.

May 4, 2021

·

3 min read

·

Mark Terry

Genetown

Neuroelectrics Raises $17.5M to Advance Clinical Trials for the Treatment of Epilepsy and Major Depressive Disorder with a New Platform for Treating Brain Dysfunction

Neuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures.

May 4, 2021

·

5 min read

Genetown

Neuroelectrics Announces Positive Results for Treatment of Medication-Resistant Epilepsy Using Starstim™

At the recent American Epilepsy Society Annual Meeting in New Orleans, Neuroelectrics Corporation presented positive results from its clinical trial treating patients with drug resistant epilepsy with Starstim™, a device that uses mild electric currents applied on the scalp to calm abnormal activity of the brain.

February 25, 2019

·

3 min read

Business

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

September 18, 2024

·

3 min read

Business

iMotions And Neuroelectrics Partner To Combine Innovative EEG Solutions With Supplementary Biometric Sensors

October 4, 2017

·

2 min read

Drug Development

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

July 10, 2024

·

5 min read

Business

Neuroelectrics Expands To U.S., Opens Office In Cambridge, Massachusetts

February 13, 2014

·

4 min read

Pharm Country

New Investigational Drug Offers Relief for Treatment-Resistant Epilepsy Patients

In cases where standard therapies fail, an investigational medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.

October 9, 2023

·

6 min read